Jean-Louis Wemeau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jean-Louis Wemeau has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Marie-Christine Vantyghem
Department of Endocrinology, Diabetology, Oncology and Metabolism, CHU Lille, Inserm U1190, EGID, University of Lille , 59045 Lille
3 shared publications - Philippe Caron
Department of Endocrinology and Metabolic Diseases, Cardiovascular and Metabolic Unit, CHU Larrey, Toulouse, France
3 shared publications - Anne-Sophie Balavoine
Service of Endocrinology and Metabolic Diseases, CHRU de Lille , Lille, France
2 shared publications - Christine Do Cao
Department of Endocrinology, Centre Hospitalier Universitaire Lille, 59000 Lille, France
2 shared publications - Emmanuelle Leteurtre
Anatomopathology Department, CHRU de Lille, Lille, France
2 shared publications - Françoise Borson-Chazot
Endocrinology Federation, hôpital Louis-Pradel, hospices civils de Lyon, université Lyon 1, 28, avenue Doyen-Lépine, 69500 Bron, France
2 shared publications
Latest Publications
- 1 February 2014
- Published by Elsevier in La Presse Médicale
- Vol. 43 (2) , 105-108
Antithyroïdiens de synthèse : que choisir ?
- 1 February 2014
- Published by Elsevier in La Presse Médicale
- Vol. 43 (2) , 105-108
Antithyroïdiens de synthèse : que choisir ?
- 1 December 2013
- Published by Elsevier in La Presse Médicale
- Vol. 42 (12) , 1596-1606
Main et maladies endocriniennes
- 1 December 2013
- Published by Elsevier in La Presse Médicale
- Vol. 42 (12) , 1596-1606
Main et maladies endocriniennes
- 1 November 2013
- Published by Elsevier in La Presse Médicale
- Vol. 42 (11) , 1486
Gynécologie endocrinienne : une séduisante discipline
- 1 November 2013
- Published by Elsevier in La Presse Médicale
- Vol. 42 (11) , 1486
Gynécologie endocrinienne : une séduisante discipline
- 1 May 2013
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 74 (2) , 157
Hibernoma and type 1 multiple endocrine neoplasia (MEN1)? A metabolic link?
- 1 May 2013
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 74 (2) , 157
Hibernoma and type 1 multiple endocrine neoplasia (MEN1)? A metabolic link?
- 1 September 2011
- Vol. 40, 793-826
[Recommendations of the French Society of Endocrinology for the management of thyroid nodules].
- 1 September 2011
- Vol. 40, 793-826
[Recommendations of the French Society of Endocrinology for the management of thyroid nodules].
- 1 June 2011
- Published by The Endocrine Society
- p. OR32-6
Phenotype, SLC12A3 Genotype and Outcome of Adult Hypokalemic Patients with Inappropriate Kaliuresis Suggesting Gitelman Syndrome (GS)
GS is a rare tubulopathy caused by SLC12A3 gene mutations which encodes the renal thiazide-sensitive sodium chloride co-transporter NCC, leading to hypokalemic alkalosis, secondary hyperaldosteronism, hypomagnesemia and hypocalciuria, usually diagnosed in young adults. The aim of this study was to assess the prevalence of SLC12A3 gene mutations in adult hypokalemic patients with inappropriate kaliuresis, to compare the phenotype of homozygous, heterozygous and non-mutated patients, and to determine the efficiency of treatment on blood potassium levels.
- 1 June 2011
- Published by The Endocrine Society
- p. OR32-6
Phenotype, SLC12A3 Genotype and Outcome of Adult Hypokalemic Patients with Inappropriate Kaliuresis Suggesting Gitelman Syndrome (GS)
GS is a rare tubulopathy caused by SLC12A3 gene mutations which encodes the renal thiazide-sensitive sodium chloride co-transporter NCC, leading to hypokalemic alkalosis, secondary hyperaldosteronism, hypomagnesemia and hypocalciuria, usually diagnosed in young adults. The aim of this study was to assess the prevalence of SLC12A3 gene mutations in adult hypokalemic patients with inappropriate kaliuresis, to compare the phenotype of homozygous, heterozygous and non-mutated patients, and to determine the efficiency of treatment on blood potassium levels.
- 1 May 1999
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 84 (5) , 1700-1704
A Novel 9-Base Pair Duplication in RET Exon 8 in Familial Medullary Thyroid Carcinoma1
Familial medullary thyroid carcinoma (FMTC) and multiple endocrine neoplasia type 2A syndromes are dominantly inherited diseases caused by activating germline mutations of the RET protooncogene. The majority of these patients carry a germline point mutation affecting one of five cysteine residues encoded by exon 10 (codon 609, 611, 618, or 620) or 11 (codon 634). In a few FMTC families, point mutations involving noncysteine codons in exon 13 (codons 768, 790, and 791), 14 (codon 804), or 15 (codon 891) have been reported. Hirschsprung’s disease is a nonneoplastic disorder associated with RET mutations leading to a loss of function effect. Mutations are identified in 50% of the familial cases and are scattered along the gene. We now report the study of a FMTC family with four affected members and a history of fatal neonatal intestinal obstruction in the sister of the proband. Genetic analysis demonstrated the absence of an usual FMTC mutation and the presence of a germline 9-bp duplication in RET exon 8 in the heterozygous state in all patients with MTC. This new mutation creates an additional cysteine residue in the extracellular cysteine-rich domain of RET. Further studies are warranted to confirm whether this new mutation is causing MTC only or could be associated with Hirschsprung’s disease.
- 1 May 1999
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 84 (5) , 1700-1704
A Novel 9-Base Pair Duplication in RET Exon 8 in Familial Medullary Thyroid Carcinoma1
Familial medullary thyroid carcinoma (FMTC) and multiple endocrine neoplasia type 2A syndromes are dominantly inherited diseases caused by activating germline mutations of the RET protooncogene. The majority of these patients carry a germline point mutation affecting one of five cysteine residues encoded by exon 10 (codon 609, 611, 618, or 620) or 11 (codon 634). In a few FMTC families, point mutations involving noncysteine codons in exon 13 (codons 768, 790, and 791), 14 (codon 804), or 15 (codon 891) have been reported. Hirschsprung’s disease is a nonneoplastic disorder associated with RET mutations leading to a loss of function effect. Mutations are identified in 50% of the familial cases and are scattered along the gene. We now report the study of a FMTC family with four affected members and a history of fatal neonatal intestinal obstruction in the sister of the proband. Genetic analysis demonstrated the absence of an usual FMTC mutation and the presence of a germline 9-bp duplication in RET exon 8 in the heterozygous state in all patients with MTC. This new mutation creates an additional cysteine residue in the extracellular cysteine-rich domain of RET. Further studies are warranted to confirm whether this new mutation is causing MTC only or could be associated with Hirschsprung’s disease.